A number of other equities research analysts have also commented on MRKR. Zacks Investment Research lowered TapImmune from a buy rating to a hold rating in a research report on Wednesday, July 17th. Nomura restated a buy rating and set a $16.00 price target on shares of TapImmune in a research report on Tuesday, August 13th. Janney Montgomery Scott restated a buy rating on shares of TapImmune in a research report on Sunday, July 21st. Oppenheimer started coverage on TapImmune in a research report on Wednesday, July 3rd. They issued an outperform rating and a $15.00 price objective on the stock. Finally, Roth Capital started coverage on TapImmune in a research report on Thursday, May 30th. They issued a buy rating and a $10.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. TapImmune currently has an average rating of Buy and a consensus target price of $10.21.
NASDAQ MRKR opened at $5.03 on Wednesday. The firm has a market cap of $253.93 million, a PE ratio of -3.01 and a beta of 0.22. TapImmune has a one year low of $3.97 and a one year high of $10.60. The stock’s 50 day simple moving average is $6.08 and its 200 day simple moving average is $5.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 16.85 and a quick ratio of 16.85.
TapImmune (NASDAQ:MRKR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. As a group, equities analysts expect that TapImmune will post -0.51 earnings per share for the current year.
In other news, insider Peter L. Hoang acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were purchased at an average cost of $4.62 per share, for a total transaction of $46,200.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 23.70% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in TapImmune stock. Riggs Asset Managment Co. Inc. raised its position in TapImmune Inc. (NASDAQ:MRKR) by 68.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 45,919 shares of the company’s stock after buying an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 as of its most recent filing with the SEC. 37.31% of the stock is currently owned by institutional investors and hedge funds.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
See Also: What is operating income?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.